Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sergey Ayzenberg

Cardiovascular Disease Brooklyn, NY Medical Doctor

NPI 1306031125 CMS profile 13914

4802 10Th Ave, Ste K1, Brooklyn, NY 11219

Open in the dashboard

General payments

$156,936

727 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,280 paid to institutions, not to them · program year 2025

Through program year 2025, Sergey Ayzenberg of Brooklyn, NY is reported in the CMS Open Payments database as having received $156,936 across 727 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,280 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40,768 140
2024 General $28,519 151
2023 General $18,801 116
2022 General $18,066 77
2021 General $14,472 68
2020 General $8,078 52
2019 General $28,231 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sergey Ayzenberg
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Sergey Ayzenberg were reported at $40,768. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Sergey Ayzenberg Cardiovascular Disease median Middle half National median
2019 $28,231 $450 $127–$1,392 $163
2020 $8,078 $242 $77–$751 $114
2021 $14,472 $335 $101–$1,037 $132
2022 $18,066 $395 $121–$1,211 $149
2023 $18,801 $443 $136–$1,283 $160
2024 $28,519 $450 $136–$1,323 $164
2025 $40,768 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $95,346 188 payments
  2. Shockwave Medical, Inc $21,407 45 payments
  3. Medtronic, Inc. $20,204 126 payments
  4. Cook Medical LLC $2,644 54 payments
  5. Boston Scientific Corporation $2,118 21 payments
  6. Cook Incorporated $1,886 4 payments
  7. Abiomed $1,717 15 payments
  8. Cardiovascular Systems Inc. $1,587 21 payments
  9. Asahi Intecc USA, Inc. $1,489 7 payments
  10. Philips Electronics North America Corporation $1,450 17 payments
  11. Other $7,088 229 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $100,287 49 payments
  2. Food and Beverage $31,628 619 payments
  3. Consulting Fee $9,900 9 payments
  4. Travel and Lodging $8,521 46 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $6,600 4 payments
Products named General payments · program years 2019–2025
  1. Repatha Cardiology $83,454 157 payments
  2. SYMPLICITY G3 $14,560 48 payments
  3. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $11,778 23 payments
  4. REPATHA Cardiovascular $11,763 29 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $9,198 18 payments
  6. ONYX FRONTIER $2,459 39 payments
  7. RESOLUTE ONYX $2,066 21 payments
  8. Impella $1,552 13 payments
  9. Zilver Vena $1,538 7 payments
  10. Coronary Other $1,169 9 payments
  11. Other $17,455 394 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

6,667

Median for Cardiology: 2,533

Drug cost

$915,553

Median for Cardiology: $485,213

Branded share of claims

36.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 396 $306,396
Repatha Sureclick Evolocumab Brand 327 $203,893
Entresto Sacubitril/Valsartan Brand 110 $84,099
Brilinta Ticagrelor Brand 144 $83,380
Xarelto Rivaroxaban Brand 31 $32,473
Multaq Dronedarone Hcl Brand 28 $26,071
Vascepa Icosapent Ethyl Brand 69 $23,379
Mounjaro Tirzepatide Brand 21 $22,716
Praluent Pen Alirocumab Brand 35 $19,601
Diclofenac Sodium Generic 14 $10,403

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$223,511

Medicare's payments for the services billed

Medicare patients

1,092

Average age 77

Services billed

3,281

569 women, 523 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 69%
Ischemic heart disease 68%
Arthritis 66%
Heart failure 39%
Atrial fibrillation 31%
Depression 30%
Chronic kidney disease 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
$13,650 327 —
ELIQUIS
$108 396 —
VERQUVO
$66 — —
Arcalyst
$65 — —
ENTRESTO
$56 110 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

727 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record